The global leukocyte adhesion deficiency management market is poised for significant growth, with projections indicating a valuation of US$ 8.09 billion by 2023 and expected to reach US$ 15.2 billion by 2033, marking a substantial Compound Annual Growth Rate (CAGR) of 6.51% during the forecast period.
The surge in research and development endeavors aimed at enhancing the efficacy of immunodeficiency therapeutics stands as a primary driver propelling market expansion. Notably, a study published by the National Institute of Health (NIH) in May 2021 highlights promising results. The investigational research, conducted across the United States and the United Kingdom and supported by NIH, revealed that 96% of children administered with novel experimental lentiviral gene therapy for immunodeficiency diseases reported restored immune function, underscoring the potential of innovative approaches in disease management.
Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16552
Moreover, the evolution of technology within the genetics realm is anticipated to further fuel the growth of the global leukocyte adhesion deficiency therapeutics market. Recent advancements, such as Next Generation Sequencing (NGS), as elucidated in an article published in the Genes & Diseases international scientific journal in March 2020, have empowered researchers to delve deeper into genetic variations associated with common variable immunodeficiency (CVID). These strides not only enhance diagnostic capabilities but also pave the way for more targeted and effective therapeutic interventions.
The convergence of intensified research activities and technological breakthroughs underscores a pivotal moment in the trajectory of leukocyte adhesion deficiency management, with immense potential to improve patient outcomes and advance the standards of care worldwide.
As the market continues to evolve, stakeholders across the healthcare spectrum are encouraged to collaborate, innovate, and invest in transformative solutions that address the unmet needs of individuals affected by immunodeficiency disorders.
Key Takeaways:
- North America is expected to dominate the industry while reaching market share of around 40.5% by end of the forecast period.
- The market in Asia Pacific is projected to reflect fastest CAGR of 6.9% during the projected timeline.
- By treatment type, the hematopoietic stem cell transplantation segment is expected to dominate the industry with a market share of 38% by 2033.
- Hospitals are projected to account for 71% market share by end-user, by end of 2033.
- United States is expected to dominate the market of leukocyte adhesion deficiency treatment market in the region of North America.
- In Asia-Pacific, China is projected to lead the market with a CAGR of 6.1% during the forecast period.
“Mounting research and development activities and increasing practices of utilizing stem-cell transplantation therapies to treat leukocyte adhesion deficiency will propel market during the forecast period,” comments an FMI Analyst
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16552
Competitive Landscape:
The global Leukocyte adhesion deficiency management market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are:
- Orpha Labs
- Avalo Therapeutics, Inc.
- Rocket Pharmaceuticals Inc.
- Sigma-Aldrich
- Aspen Neuroscience
- Magenta Therapeutics
- Rubius Therapeutics
- Enochian Biosciences
- Sana Biotechnology
- Vertex Pharmaceuticals
Some Recent Developments In The Market Are:
- In September 2022, Lactiga Therapeutics raised USD 1.6 million in oversubscribed pre-seed financing for developing therapeutics for patients with primary immunodeficiency diseases.
- In April 2022, Pharming Group N.V. presented positive data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.
Key Segments Profiled in the Leukocyte Adhesion Deficiency Management Industry Survey:
By Treatment:
- Hematopoietic Stem Cell Transplantation
- Recombinant Human Interferon-gamma Treatment
- Prophylactic Immunoglobulin Therapy
- Antimicrobial Therapy
- Prophylactic Therapy
- Fucose Supplementation
- Monoclonal Antibodies
- Coagulation Factors
By End Users:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/16552
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube